Wellling’s and Motinova’s New E-bike Motor Series Debut at EUROBIKE 2022
14.7.2022 05:14:00 EEST | Business Wire | Press release
Motinova’s and Welling’s latest E-bike motor series debut at EUROBIKE 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005981/en/
New Motinova and Welling E-bike motor series offerings at Booth H8-I20, EUROBIKE 2022 (Indoors) (Photo: Business Wire)
By 2030, the global E-Bike market will reach 19 million units. As the green and low-carbon lifestyle trends, E-bikes have gradually become an alternative choice for urban commuters and field riders. Welling and Motinova offer three central motors for large chain wheels: Welling W6000, Welling 8500, and Motinova MT6000, featuring higher power density, higher efficiency, shorter response time, and lower wastage rate.
Welling W6000 for urban E-bikes: This high-performing central motor for large chain wheels is compact and low-noise designed (under 52dB), enabling a quiet riding experience. Its innovative torque sensor can adapt to a highly flexible riding curve for different biking scenarios. Its algorithm allows high-precision delay and inertia compensation for a smoother and more stable riding experience.
Welling W8500 for mountain E-bikes: Its unique flat wire winding structure with optimized design can enable efficiency to reach 80%, and increase battery range in mountain biking. Its ultra-high overload capacity can run continuously at 75% peak torque while keeping the shell temperature below 60°C for longer service life and more powerful output. Its highly integrated design enables it to have a weight of less than 3 kg in a very compact size.
Motinova MT6000: This high-performing central motor for large chain wheels is designed for urban commuters. The motor is only 3 kg and is very delicate. It could provide a maximum assistance rate of 270% in a strong and quiet momentum. Its pedaling rate can reach as high as 100rpm with five riding modes. Bikers can enjoy the fun of riding in all kinds of road conditions.
Motinova motors for small chain wheels, such as the VOLANS and PEGASI series; cycle computers; accessories; and other biking offerings are also on exhibition. In the outdoor exhibition area, Motinova and Welling also provide a fun test riding experience, “Ride Longer, Live Better.”
Motinova and Welling will further enhance their core capabilities in the field of intelligent transportation and the two-wheel transportation market.
Motinova’s and Welling’s parent, Midea Industrial Technology, has built 27 R&D centers in China, Austria, India, and Japan, with an accumulation of more than 5,500 authorized patents.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005981/en/
Contact information
Zhang Haichun
zhanghc69@midea.com
+86-18600038145
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom